Constipation on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations
How common is constipation on Zepbound? A clinical breakdown of trial-reported rates, severity grades, risk factors, timeline, and practical management steps.
10 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 10 of 10 clinical reviews.
How common is constipation on Zepbound? A clinical breakdown of trial-reported rates, severity grades, risk factors, timeline, and practical management steps.
A week-by-week breakdown of when constipation starts, peaks, and typically resolves on Zepbound (tirzepatide), with trial data and management strategies for each phase.
Specific dietary, hydration, meal-timing, and supplement strategies to reduce constipation on Zepbound (tirzepatide), based on trial data and GI management evidence.
OTC and prescription options for treating constipation caused by Zepbound (tirzepatide), with first-line and second-line agents, dose ranges, and drug interactions to watch.
Evidence-based supplements for managing constipation caused by Zepbound (tirzepatide), including psyllium, magnesium, and probiotics, with dosing, trial data, and clinical guidance.
Clinical protocols for adjusting Zepbound dose titration to manage constipation, including slowing schedules, pausing, stepping down, and microdosing strategies.
Learn when constipation from Zepbound (tirzepatide) requires medical attention, why GLP-1/GIP agonists slow gut motility, and how to manage symptoms safely.
A clinical severity grading rubric for constipation caused by Zepbound (tirzepatide), including CTCAE-based grading, management strategies by grade, mechanism of action, and when to seek medical attention.
Persistent constipation on Zepbound (tirzepatide) affects up to 1 in 4 patients. Learn why it happens, evidence-based treatments, and when to contact your prescriber.
Evidence-based alternatives to Zepbound (tirzepatide) for patients who experience constipation, including management strategies, lower-risk GLP-1 options, and non-incretin weight-loss medications.